Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Next Previous
Trial Profile

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Cabozantinib (Primary) ; Paclitaxel (Primary)
  • Indications Breast cancer; Carcinoma; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Liver cancer; Ovarian cancer; Peritoneal cancer; Renal cancer; Solid tumours; Thoracic neoplasms
  • Focus Adverse reactions

Most Recent Events

  • 17 Apr 2024 Planned number of patients changed from 36 to 43.
  • 17 Apr 2024 Status changed from suspended to recruiting.
  • 02 Apr 2024 Status changed from recruiting to suspended as per the sponsor's decision, till the approval of amendment.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top